Quick Answer
AEON Biopharma, Inc. reported Operating Income Loss of -$12.80 million for the year ending 2025.
- AEON Biopharma, Inc. showed a decrease of -117.5% in Operating Income Loss from 2024 to 2025.
- This data is from AEON Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$200.9 thousand | Q2 2021: -$398.4 thousand | Q3 2021: -$450.9 thousand | Q1 2022: -$389.1 thousand | Q2 2022: -$427.2 thousand | Q3 2022: -$9.91 million | Q1 2023: -$13.05 million | Q2 2023: -$13.97 million | Q3 2023: -$2.63 million | Q3 2023: -$283.71 million | Q1 2024: -$74.15 million | Q2 2024: $153.47 million | Q3 2024: -$4.02 million | Q1 2025: -$462.0 thousand | Q2 2025: -$4.34 million | Q3 2025: -$2.49 million.
- Over the full 5 years of available data (2020 to 2025), AEON Biopharma, Inc.'s Operating Income Loss has declined by 356,728.3%.
- Historical annual values: Fiscal year 2025: -$12.80 million | Fiscal year 2024: $72.99 million | Fiscal year 2022: -$48.43 million | Fiscal year 2021: -$1.94 million | Fiscal year 2020: -$3.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: